Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Cost Effectiveness Debate Now Features The Body Bag Argument

This article was originally published in The Pink Sheet Daily

Executive Summary

Center for Medicine in the Public Interest contends that over five years, 44,000 fewer patients will be alive if ICER's cost-effectiveness calculation for multiple myeloma treatments is adopted.

Advertisement

Related Content

How To Handle Off-Label Promotion: A Guide From PhRMA And BIO
ICER Eyes QALY Ratios, Budget Impacts In Methods Review

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS079448

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel